Lifeline Scientific, Inc Posting of Annual Report & Notice of AGM (4251P)
2015年6月5日 - 11:46PM
RNSを含む英国規制内ニュース (英語)
TIDMLSIC
RNS Number : 4251P
Lifeline Scientific, Inc
05 June 2015
Lifeline Scientific
("Lifeline" or the "Company")
Posting of Annual Report & Notice of AGM
Lifeline Scientific (AIM: LSIC), the transplantation technology
company, confirms that the Annual Report and Accounts for the year
ended 31 December 2014 ("2014 Annual Report and Accounts"), the
Notice of the Annual General Meeting ("AGM") and a Form of Proxy
were posted to shareholders on 28 May 2015.
The AGM is to be held at 8:30 am US CDT on 25 June 2015 at the
Westin Hotel, 400 Park Boulevard, Itasca, IL 60143, USA.
A copy of the 2014 Annual Report and Accounts is available on
the Company's website: www.lifeline-scientific.com
For further information:
Lifeline Scientific, Inc. www.lifeline-scientific.com
David Kravitz, CEO Tel: +1 847 294 0300
Lisa Kieres, CFO Tel: +1 847 294 0300
Panmure Gordon (UK) Limited Tel: +44 (0)20 7886 2500
Freddy Crossley (Corporate
Finance)
Maisie Atkinson (Corporate
Broking)
Walbrook PR Limited Tel: +44 (0) 20 7933 8780 or lifeline@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product, LifePort Kidney Transporter, is
the global market-leading medical device for hypothermic machine
preservation (HMP), of donor kidneys. LifePorts and novel solutions
designed for preservation of other organs are in development, with
LifePort Liver Transporter next in line for commercial launch. For
more information please visit www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to help improve kidney preservation, evaluation and
transport prior to transplantation. It has been widely studied in
clinical trials throughout the world and is the standard of care
for machine preservation of kidneys. Employed by surgeons in over
190 leading transplant programmes in 28 countries, LifePorts have
successfully preserved over 55,000 kidneys indicated for clinical
transplant. For more information please visit
www.organ-recovery.com
About LifePort Liver Transporter
LifePort Liver Transporter is modelled upon the clinically
proven technology platform of LifePort Kidney Transporter. The
Company's early liver HMP prototype was successfully used under a
US FDA Investigational Device Exemption in clinical transplant
studies by surgeons at New York-Presbyterian Hospital/Columbia
University Medical Center. LifePort Liver Transporter and the
Company's proprietary machine preservation solution, Vasosol(R),
are in the process of US and European regulatory registrations. The
system is designed to help improve outcomes in liver
transplantation by enabling the clinical use of hypothermic machine
perfusion, and has been developed in consultation with clinical and
research teams specializing in liver transplantation at Columbia
University Medical Center and the University of Chicago. The system
employs a rugged, streamlined ergonomic design for ease of use and
transportability from donor bedside to recipient operating room.
For more information please visit:
http://www.organ-recovery.com/pipeline.php
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEALKSELSSEFF
Lifeline Sci (LSE:LSIC)
過去 株価チャート
から 6 2024 まで 7 2024
Lifeline Sci (LSE:LSIC)
過去 株価チャート
から 7 2023 まで 7 2024